A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 467-471

  Mercolini, Laura ^a   Protti, Michele ^a   Fulgenzi, Giulia ^a   Mandrioli, Roberto ^a   Ghedini, Nadia ^a   Conca, Andreas ^b   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Health Agency of South Tyrol   (Italy)

Author keywords

HPLC; Microextraction by packed sorbent (MEPS); Plasma; Therapeutic drug monitoring (TDM); Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MIRTAZAPINE; SORBENT; ZIPRASIDONE;

ARTICLE; CHROMATOGRAPHY; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MENTAL PATIENT; MICROEXTRACTION BY PACKED SORBENT; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

HPLC; MICROEXTRACTION BY PACKED SORBENT (MEPS); PLASMA; THERAPEUTIC DRUG MONITORING (TDM); ZIPRASIDONE;

ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; LIMIT OF DETECTION; PIPERAZINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE MICROEXTRACTION; THIAZOLES;

EID: 84886802665     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.09.019     Document Type: Article

References (23)

1. Greenberg W.M., Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007, 13:137-177.
2. John M. Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review Summary Guides for Clinicians [Internet] 2012, Eisenberg Center for Clinical Decisions and Communications Science, Agency for Healthcare Research and Quality (US), Rockville, MD.
3. Stahl S.M., Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 2003, 64:6-12.
4. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19:1-93.
5. Rossi A., Vita A., Tiradritti P., Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int. Clin. Psychopharmacol. 2008, 23:216-222.
6. Mauri M.C., Colasanti A., Rossattini M., Volonteri L.S., Dragogna F., Fiorentini A., Valli A., Papa P. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 2007, 40:89-92.
7. Prakash C., Kamel A., Gummerus J., Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 1997, 25:863-872.
8. Green B. Focus on ziprasidone. Curr. Med. Res. Opin. 2001, 17:146-150.
9. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
10. Sachse J., Härtter S., Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther. Drug Monit. 2005, 27:158-162.
11. Zhang G., Terry A.V., Bartlett M.G. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 2007, 856:20-28.
12. Suckow R.F., Fein M., Correll C.U., Cooper T.B. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. J. Chromatogr. B 2004, 799:201-208.
13. Al Dirbashi O.Y., Aboul-Enein H.Y., Al-Odaib A., Jacob M., Rashed M.S. Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma. Biomed. Chromatogr. 2006, 20:365-368.
14. Kirchherr H., Kühn-Velten W.N. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J. Chromatogr. B 2006, 843:100-113.
15. Zhang G., Jr Terry A.V., Bartlett M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J. Chromatogr. B 2007, 858:276-281.
16. Aravagiri M., Marder S.R., Pollock B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J. Chromatogr. B 2007, 847:237-244.
17. Zhang G., Terry A.V., Bartlett M.G. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun. Mass Spectrom. 2007, 21:920-928.
18. Zhang G., Terry A.V., Bartlett M.G. Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2008, 22:770-778.
19. Hasselstrøm J. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2011, 879:123-128.
20. United States Pharmacopeial Convention 2009, 734. United States Pharmacopeia, Rockville, MD. 32th ed.
21. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
22. Mercolini L., Grillo M., Bartoletti C., Boncompagni G., Raggi M.A. Simultaneous analysis of classical neuroleptics, atypical antipsychotics and their metabolites in human plasma. Anal. Bioanal. Chem. 2007, 388:235-243.
23. Mandrioli R., Mercolini L., Lateana D., Boncompagni G., Raggi M.A. Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV. J. Chromatogr. B 2011, 879:167-173.